**Professor John Camm**
- Chaired a session at the AHA meeting supported by Sanofi Aventis relating to Clopidogrel (2008)
- Received travel grant from Sanofi Aventis to travel to the US (2008).

**Dr Huon Gray**
- Received honoraria from Lily advisory board (11/07)
- Received honoraria from Medicines company for advisory board on STEMI, not UA or NSTEMI (12/2008)

**Mr Sotiris Antoniou**
- Attended Advisory Board for Sanofi Aventis (re: Clopidogrel) and Lilly (re: Prasugrel) (2007)
- Received a grant from Takeda to undertake a diabetes study (2008)
- Received several travel grants from pharmaceutical companies for unrelated areas (2007)
- Wrote an editorial response to OASIS-5 trial (unpublished).
- Attended advisory boards regarding anticoagulant therapy prior to joining NICE GDG for both Sanofi Aventis and GSK.
- Chair of the Cardiac committee of United kingdom Clinical Pharmacy Association (UKCPA) (2005 – present).

**Ms Lina Bakhshi**
- None declared.

**Ms Jenny Cadman**
- None declared.

**Dr Emily Crowe**
- None declared.

**Dr Mark de Belder**
- Attended an Advisory Board for Cordis and Conor/Cordis (stent manufactures), Nycomed and Boehringer-Ingelheim (PCI-related pharmaceutical companies) (2005-2009)
- Chaired an Advisory Board for Sanofi-Aventis/Bristol-Myers Squibb (2007-2009)
- Chaired and spoke at a symposium sponsored by Daiichi-Sankyo/Lilly (2007-2009)
- Received payment for professional work done as UK PI for the Finesse (Centocor) Assesnt 4 PCI (Boehringer-Ingeheime) trials (2008)
- Working as UK PI for the REDEEM trial (Boehringer Ingleheim) (present)
- President of the British Cardiovascular Intervention Society (present)
- MDB declared that he had chair a pharmaceutical company sponsored symposium and attended an advisory board for SKF on matters relating to antiplatelet therapy.

**Dr Jose Diaz**
- None declared.

**Mr David H. Geldard**
- None declared.

**Dr Robert Henderson**
- Received honoraria for Advisory Board from Cordis UK (2007) and Abbott Vascular (2009)
• Received travel grants to attend conferences from Cordis UK and Boston Scientific (2008), Daichii Sankyo/Lilly (2008), Abbott Vascular (2009).
• Member of the British Cardiovascular Intervention Society Council (2006 – present)

Professor Marjan Jahangiri
• None declared.

Ms Taryn Krause
• None declared.

Miss Kate Lovibond
• In 2007 worked for a healthcare communications agency on one-off projects:
  o Enoxaparin (Lovenox; Sanofi-Aventis) – non-ACS-related project
  o Fondaparinux (Arixtra; GlaxoSmithKline) – ACS-related health economics project
  o Valsartan (Diovan, Diovan HCT, Exforge; Novartis) – non-ACS-related project

Mr Gavin Maxwell
• None declared.

Dr Francis Morris
• None declared.

Mr Alun Roebuck
• Launched a public and private industry partnership in cardiac genetics involving several educational grants from pharmaceutical companies that go directly to trust and are ACS related.

Ms Nicola Sloan
• None declared.

Ms Claire Turner
• None declared.

Professor S. Richard Underwood
• Lead clinician at Quantum Inhealth (private healthcare section), Nuclear medicine imaging clinic (present)
• Received honoraria for Advisory Board from GE Healthcare (25/06/09)
• Received research funding from GE Healthcare and Cardiovascular Therapeutics Inc. (2007-08)
• Received training course funding from CE Healthcare and Bristol Myers Squibb (Feb 2008 + Feb 2009)
• Senate member, ESC Working Group in nuclear cardiology and CT (2005 - current)

Mr Mark Whitbread
• None declared.

Mr Jo Smith (deputy for Mark Whitbread, 26 February 2009)
• None declared.

Professor Keith Fox (attended GDG 8 as an invited expert)
• Received honoraria for lectures from Sanofi-Aventis, GSK, MSD
• Received departmental grants from Sanofi-Aventis, MSD, GSK, Lilly, University of Massachusetts, Duke University

K. Angelini
• None declared.